Episode Details

In this episode of The BioHub Podcast, Max sits down with Andrew Obenshain, CEO of Inventiva.

Andrew brings more than 20 years of experience across global drug development, regulatory strategy, and commercialization. Before joining Inventiva, he led bluebird bio through its transformation into a global commercial-stage gene therapy company and previously held senior leadership roles at Shire and Genzyme.

Inventiva is a late-stage clinical biopharmaceutical company developing oral therapies for patients with significant unmet medical needs, with its lead program focused on MASH (metabolic dysfunction-associated steatohepatitis).

In this conversation, we discuss Andrew's journey through global biotech leadership, why he chose to lead a French biotech company, the challenges of running a late-stage clinical business, and what makes Inventiva's approach so exciting.

We also explore the strengths of the European biotech ecosystem, the milestones ahead for Inventiva, and the leadership lessons Andrew has learned throughout his career.